Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Julia Sahin

EA to the Vice-Provost (Enterprise)

Julia Sahin

T: 020 7679 7538
E: j.sahin@ucl.ac.uk

Julia is Executive Assistant to the Vice-Provost (Enterprise) and is responsible for managing his diary and day-to-day correspondence, as well as coordinating corporate reporting from the Office of the Vice-Provost (Enterprise) and being departmental administrator for the office of the Vice-Provost (Enterprise). She is also secretary to the Enterprise Steering Committee.

Before joining UCL Enterprise, Julia worked for the General Teaching Council for England, and previously City University.